This trial is active, not recruiting.

Condition chronic kidney disease
Treatment sarpogrelate
Phase phase 4
Sponsor Seoul National University Boramae Hospital
Start date December 2009
End date December 2010
Trial size 212 participants
Trial identifier NCT01165567, 20091104/06-2009-123/89



Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clear defined and debatable. Therefore additional prophylactic pretreatments are needed.


Present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) a routine treatment without sarpogrelate group (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.


As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
sarpogrelate Anplag
sarpogrelate, 300mg/day,duration: 4 weeks
(No Intervention)

Primary Outcomes

incidence of contrast-induced nephropathy
time frame: within 48 hours after using a contrast agent

Secondary Outcomes

occurrence of CIN
time frame: at 4 weeks after using a contrast agent

Eligibility Criteria

Male or female participants from 20 years up to 85 years old.

Inclusion Criteria: - patient with chronic kidney disease scheduled for coronary angiogram Exclusion Criteria: - age less than 20 years or more than 85 years - liver cirrhosis greater than or equal to Child class B - decreased serum platelet level (< 100,000/uL) - patients who received or are schedule to receive percutaneous renal intervention - currently are taking anticoagulation drugs - unable to give informed consent

Additional Information

Official title Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy
Description All patients with CKD scheduled for CAG will be eligible, assuming their ability to understand the character and individual consequences of participation as well as giving written informed consent. CKD is defined as estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m2 using modification of diet in renal disease (MDRD) formula or serum creatinine (Cr) > 1.5 mg/dL. The MDRD formula was defined in the following way. Where the Cr concentration is in mg/dL: eGFR = 186 × serum Cr−1.154 × Age−0.203 × (0.742 if female) Exclusion criteria are age less than 20 years or more than 85 years, liver cirrhosis greater than or equal to Child class B, decreased serum platelet level (< 100,000/uL), patients who received or are schedule to receive percutaneous renal intervention, currently are taking anticoagulation drugs, unable to give informed consent. Patients in shock, maintaining hemodialysis, hemofiltration, peritoneal dialysis will be excluded.
Trial information was received from ClinicalTrials.gov and was last updated in July 2010.
Information provided to ClinicalTrials.gov by Seoul National University Boramae Hospital.